Search ARM

About ARM


ARM represents 400+ members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations


ARM represents 400+ members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations

Who We Are

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis. We actively engage key stakeholders to enable the development of advanced therapies and to modernize healthcare systems so that patients benefit from durable, potentially curative treatments.

As the global voice of the sector, we represent more than 400 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations.

Our Focus

Convening the sector

  • Gathering industry executives and senior leaders at our first-in-class conferences in North America and Europe
  • Hosting exclusive workshops and webinars that facilitate influential exchanges on topics related to policy and practice

Advancing the narrative with data and analysis

  • Generating original data and analyses to inform patients, industry stakeholders, policymakers, and the media
  • Advancing a narrative to demonstrate the transformational value cell and gene therapies have for patients and healthcare systems

Engaging key stakeholders

  • Working with public agencies to support collaboration between government and industry
  • Building a network of champions for cell and gene therapies

Enabling the development of advanced therapies

  • Collaborating with manufacturing and technology experts to reduce barriers to product development
  • Providing insight and analysis on future technologies and trends that will shape the sector

Modernizing healthcare systems

  • Advocating for policies that will enhance patient access to cell and gene therapies
  • Ensuring fair, robust, and expedient regulatory pathways

Our Impact

In collaboration with our members, ARM has been behind many historic cell and gene therapy policy wins. For example, ARM lobbied for the creation of a new FDA pathway, the Regenerative Medicine Advanced Therapy (RMAT) Designation, to accelerate CGT development. ARM also hosted an FDA-ARM Scientific Exchange in 2022 that helped lead to the development of a draft 2024 guidance on “Potency Assurance for Cellular and Gene Therapy Products,” which introduces new flexibility.

ARM is also a leading convener of executives and senior leaders in cell and gene therapy. Our two annual meetings in the U.S. and Europe welcome a combined 2,500+ attendees, over a quarter of whom hold C-suite positions.